MCID: MSC004
MIFTS: 37

Muscle Tissue Disease

Categories: Muscle diseases

Aliases & Classifications for Muscle Tissue Disease

MalaCards integrated aliases for Muscle Tissue Disease:

Name: Muscle Tissue Disease 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:66

Summaries for Muscle Tissue Disease

MalaCards based summary : Muscle Tissue Disease is related to lopes gorlin syndrome and d-minus hemolytic uremic syndrome. An important gene associated with Muscle Tissue Disease is DMD (Dystrophin), and among its related pathways/superpathways are Arrhythmogenic right ventricular cardiomyopathy (ARVC) and Non-integrin membrane-ECM interactions. The drugs Benzocaine and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and skeletal muscle, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Muscle Tissue Disease

Diseases related to Muscle Tissue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
id Related Disease Score Top Affiliating Genes
1 lopes gorlin syndrome 11.0 DMD DYSF
2 d-minus hemolytic uremic syndrome 11.0 DMD UTRN
3 corneal dystrophy, subepithelial mucinous 10.9 GNE PABPN1
4 dsg2-related dilated cardiomyopathy 10.9 DMD SGCA
5 stargardt disease, autosomal recessive 10.9 SMN1 SMN2
6 anonychia congenita 10.9 CAPN3 DMD
7 adrenal carcinoma 10.9 ANO5 DYSF
8 lethal congenital contracture syndrome 5 10.9 MTM1 RYR1
9 retinitis pigmentosa with or without skeletal anomalies 10.9 MSTN SMN1 SMN2
10 galactorrhoea-hyperprolactinaemia 10.9 FKRP FKTN
11 cardiomyopathy, dilated, 1d 10.9 DAG1 DMD LAMA2
12 pain disorder 10.9 SMN1 SMN2
13 obesity due to sim1 deficiency 10.9 FKRP FKTN
14 ullrich congenital muscular dystrophy 1 10.9 CAPN3 DMD DYSF
15 hereditary angioedema 10.9 DMD MTM1 RYR1
16 hypertrophic cardiomyopathy 21 10.9 CAPN3 DYSF SGCA
17 multiple endocrine neoplasia 10.9 CAPN3 DMD FKRP
18 osteogenesis imperfecta with opalescent teeth, blue sclerae and wormian bones but without fractures 10.8 CAPN3 DYSF FKRP
19 cardiomyopathy, hypertrophic, 25 10.8 CAPN3 DYSF FKRP
20 autosomal recessive nonsyndromic deafness 3 10.8 DAG1 DMD FKTN LAMA2
21 arthrogryposis, distal, type 2a 10.8 EMD RYR1
22 creatine phosphokinase, elevated serum 10.8 DYSF FKRP MSTN
23 properdin deficiency 10.8 DMD SGCA
24 miyoshi muscular dystrophy 1 10.8 CAPN3 DYSF
25 spinal muscular atrophy-3 10.8 SMN1 SMN2
26 muscular dystrophy, rigid spine, 1 10.8 ANO5 DMD DYSF LAMA2
27 nevus cavernosus 10.8 CLCN1 DMD MSTN
28 mct8-specific thyroid hormone cell-membrane transporter deficiency 10.8 CAPN3 DYSF SGCA
29 hirschsprung disease 5 10.8 FKRP FKTN
30 parametrium malignant neoplasm 10.8 DMD EMD LAMA2
31 cardiomyopathy, dilated, 1a 10.8 DAG1 DMD EMD LAMA2
32 salih myopathy 10.7 CAPN3 FKRP
33 microcephaly and chorioretinopathy 1 10.7 DMD DYSF EMD RYR1
34 major affective disorder 4 10.7 DMD RYR1
35 cubitus valgus with mental retardation and unusual facies 10.7 DMD EMD GNE LAMA2
36 charcot-marie-tooth disease, type 2b2 10.7 CAPN3 DYSF FKRP LAMA2
37 scn1b-related generalized epilepsy with febrile seizures plus 10.7 DAG1 DMD DYSF SGCA UTRN
38 complement component c2 deficiency 10.7 DAG1 DMD FKRP FKTN
39 erythema elevatum diutinum 10.7 SMN1 SMN2
40 acetyl-coa carboxylase deficiency 10.7 CAPN3 DYSF FKRP SGCA
41 miyoshi muscular dystrophy 3 10.7 ANO5 DYSF FKRP FKTN
42 pulmonary hypertension, primary, 2 10.7 CAPN3 DAG1 DMD DYSF SGCA
43 autosomal recessive limb-girdle muscular dystrophy type 2f 10.7 CAPN3 DYSF FKRP SGCA
44 autosomal recessive limb-girdle muscular dystrophy type 2h 10.7 CAPN3 DYSF FKRP SGCA
45 antley-bixler syndrome 10.7 DAG1 FKRP FKTN
46 lyme disease 10.7 ANO5 CAPN3 DMD DYSF GNE
47 usher syndrome 10.7 DMD EMD RYR1 SGCA
48 allergic bronchopulmonary aspergillosis, familial 10.7 DYSF EMD GNE MSTN
49 cerebellar ataxia and hypogonadotropic hypogonadism 10.6 DAG1 DMD FKTN LAMA2 SGCA
50 pseudoachondroplastic dysplasia 2 10.6 SMN1 SMN2

Graphical network of the top 20 diseases related to Muscle Tissue Disease:



Diseases related to Muscle Tissue Disease

Symptoms & Phenotypes for Muscle Tissue Disease

MGI Mouse Phenotypes related to Muscle Tissue Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 CLCN1 DAG1 DMD DYSF EMD FKRP
2 homeostasis/metabolism MP:0005376 10.2 SGCA SMN2 UTRN CAPN3 CLCN1 DAG1
3 growth/size/body region MP:0005378 10.18 MSTN MTM1 RYR1 SMN2 UTRN CAPN3
4 cardiovascular system MP:0005385 10.14 CAPN3 DAG1 DMD EMD GNE MSTN
5 muscle MP:0005369 10.09 SGCA SMN2 UTRN CAPN3 CLCN1 DAG1
6 mortality/aging MP:0010768 10.03 MTM1 RYR1 SMN2 UTRN CLCN1 DAG1
7 no phenotypic analysis MP:0003012 9.5 CAPN3 CLCN1 DMD DYSF MSTN MTM1
8 skeleton MP:0005390 9.28 CLCN1 DMD FKRP LAMA2 MSTN MTM1

Drugs & Therapeutics for Muscle Tissue Disease

Drugs for Muscle Tissue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1246)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-24-8 5755
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
7
Rocuronium Approved Phase 4,Phase 3,Phase 2,Phase 1 119302-91-9, 143558-00-3 441290
8
Succinylcholine Approved Phase 4,Phase 3,Phase 2 306-40-1 5314
9
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1 202409-33-4 123619
10
Milnacipran Approved Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
11
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1 50-48-6 2160
12
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2 303-53-7 2895
13
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
14
Ramipril Approved Phase 4 87333-19-5 5362129
15
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
16
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 60142-96-3 3446
17
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1 58-39-9 4748
18
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
19
Sodium oxybate Approved Phase 4,Phase 3,Phase 2 502-85-2 5360545
20
Dinoprostone Approved Phase 4 363-24-6 5280360
21
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 1,Phase 2 128-13-2 31401
22
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
23
Moxonidine Approved Phase 4 75438-57-2 4810
24
Ranolazine Approved, Investigational Phase 4,Phase 2 142387-99-3, 95635-55-5 56959
25
Magnesium oxide Approved Phase 4 1309-48-4 14792
26
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
27
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
28
Thrombin Approved Phase 4
29
Letrozole Approved, Investigational Phase 4,Phase 2 112809-51-5 3902
30
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 33069-62-4 36314
31 Trapidil Approved Phase 4 15421-84-8
32
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1744-22-5 5070
33
Amlodipine Approved Phase 4 88150-42-9 2162
34
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
35
Valsartan Approved, Investigational Phase 4,Phase 2,Phase 1 137862-53-4 60846
36
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
37
Levodopa Approved Phase 4,Phase 2,Early Phase 1 59-92-7 6047
38
Diazepam Approved, Illicit, Vet_approved Phase 4,Early Phase 1 439-14-5 3016
39
Bezafibrate Approved Phase 4,Phase 3,Phase 2 41859-67-0 39042
40
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 137-58-6 3676
41
Polidocanol Approved Phase 4,Phase 2 9002-92-0
42
Mivacurium Approved Phase 4,Phase 2 106791-40-6, 133814-19-4 5281042
43
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2 15307-86-5 3033
44
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
45
Sevoflurane Approved, Vet_approved Phase 4,Phase 2 28523-86-6 5206
46
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
47
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
48
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 103-90-2 1983
49
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
50
Naproxen Approved, Vet_approved Phase 4,Phase 1 22204-53-1 1302 156391

Interventional clinical trials:

(show top 50) (show all 6626)

id Name Status NCT ID Phase Drugs
1 Identification of Carnitine-Responsive Cardiomyopathy Unknown status NCT01904396 Phase 4 Carnitine
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
4 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
5 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
6 Aliskiren and Muscle Sympathetic Nerve Activity Unknown status NCT00719316 Phase 4 Aliskiren
7 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Unknown status NCT01901224 Phase 4 Metformin 1000 mg;Placebo
8 A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon Unknown status NCT01341509 Phase 4
9 Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine Unknown status NCT01941628 Phase 4 Rocuronium;Succinylcholine
10 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4 etoricoxib
11 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
12 The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation Unknown status NCT01825304 Phase 4
13 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
14 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4 carvedilol;ramipril
15 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
16 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
17 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
18 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
19 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
20 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
21 Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain Unknown status NCT02339662 Phase 4 Gabapentin;Amitriptyline
22 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
23 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
24 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
25 Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis Unknown status NCT00173706 Phase 4 L-Carnitine Injection
26 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
27 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
28 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
29 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
30 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
31 CPAP for Infantile Pompe Disease Unknown status NCT02405624 Phase 4
32 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
33 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
34 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
35 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
36 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
37 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
38 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
39 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4 profound neuromuscular blockade
40 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
41 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
42 Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin Unknown status NCT00370045 Phase 4 Bivalirudin with and without eptifibatide
43 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
44 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
45 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
46 Inspiratory Muscle Training in Patients With End Stage Renal Failure Unknown status NCT01347775 Phase 4
47 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
48 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
49 Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ Unknown status NCT00914420 Phase 4
50 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4

Search NIH Clinical Center for Muscle Tissue Disease

Genetic Tests for Muscle Tissue Disease

Anatomical Context for Muscle Tissue Disease

MalaCards organs/tissues related to Muscle Tissue Disease:

39
Heart, Brain, Skeletal Muscle, Testes, Bone, Kidney, Spinal Cord

Publications for Muscle Tissue Disease

Variations for Muscle Tissue Disease

Expression for Muscle Tissue Disease

Search GEO for disease gene expression data for Muscle Tissue Disease.

Pathways for Muscle Tissue Disease

GO Terms for Muscle Tissue Disease

Cellular components related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 filopodium GO:0030175 9.56 DAG1 DMD MTM1 UTRN
2 Z disc GO:0030018 9.55 CAPN3 DMD FBXO32 SMN1 SMN2
3 costamere GO:0043034 9.52 DAG1 DMD
4 SMN-Sm protein complex GO:0034719 9.51 SMN1 SMN2
5 T-tubule GO:0030315 9.5 CAPN3 DYSF RYR1
6 filopodium membrane GO:0031527 9.49 DMD UTRN
7 SMN complex GO:0032797 9.46 SMN1 SMN2
8 Gemini of coiled bodies GO:0097504 9.43 SMN1 SMN2
9 contractile ring GO:0070938 9.4 DAG1 UTRN
10 dystroglycan complex GO:0016011 9.37 DAG1 SGCA
11 dystrophin-associated glycoprotein complex GO:0016010 9.35 DAG1 DMD FKRP SGCA UTRN
12 sarcolemma GO:0042383 9.23 CLCN1 DAG1 DMD DYSF FKRP LAMA2
13 cytoplasm GO:0005737 10.32 CAPN3 DAG1 DMD EMD FBXO32 GNE

Biological processes related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 muscle contraction GO:0006936 9.7 CLCN1 DYSF EMD PABPN1 RYR1 SGCA
2 muscle cell cellular homeostasis GO:0046716 9.62 CAPN3 DMD MSTN MTM1
3 skeletal muscle tissue regeneration GO:0043403 9.56 DAG1 DMD MSTN SGCA
4 negative regulation of protein kinase B signaling GO:0051898 9.54 DAG1 MSTN MTM1
5 nuclear import GO:0051170 9.49 SMN1 SMN2
6 response to muscle activity GO:0014850 9.48 CAPN3 MSTN
7 protein O-linked mannosylation GO:0035269 9.46 FKRP FKTN
8 DNA-templated transcription, termination GO:0006353 9.43 SMN1 SMN2
9 Schwann cell differentiation GO:0014037 9.4 DAG1 LAMA2
10 response to denervation involved in regulation of muscle adaptation GO:0014894 9.35 DAG1 DMD FBXO32 SGCA UTRN
11 muscle organ development GO:0007517 9.23 CAPN3 DMD EMD FKTN LAMA2 MSTN

Molecular functions related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 actin binding GO:0003779 9.56 DAG1 DMD EMD UTRN
2 dystroglycan binding GO:0002162 9.16 DAG1 DMD
3 structural constituent of muscle GO:0008307 9.13 CAPN3 DAG1 DMD
4 vinculin binding GO:0017166 8.8 DAG1 DMD UTRN

Sources for Muscle Tissue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....